Provided by Tiger Trade Technology Pte. Ltd.

Corcept Therapeutics

122.25
+1.200.99%
Post-market: 122.250.00000.00%19:58 EDT
Volume:656.44K
Turnover:80.15M
Market Cap:13.22B
PE:269.48
High:123.44
Open:121.48
Low:120.56
Close:121.05
52wk High:123.44
52wk Low:28.66
Shares:108.10M
Float Shares:96.44M
Volume Ratio:0.88
T/O Rate:0.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4537
EPS(LYR):0.8200
ROE:8.23%
ROA:0.47%
PB:18.72
PE(LYR):149.09

Loading ...

Corcept Therapeutics Inc : Canaccord Genuity Raises Target Price to $150 from $135

THOMSON REUTERS
·
Jul 29

Corcept Therapeutics Cut to Underperform from Peer Perform by Wolfe Research

Dow Jones
·
Jul 27

Top Growth Companies With Insider Ownership For July 2026

Simply Wall St.
·
Jul 27

Movement Alert|Corcept Therapeutics Rises 5.36% in Regular Trading, Cushing Syndrome NDA Resubmission and Earnings Expectations Boost Sentiment

Market Focus
·
Jul 24

Corcept Therapeutics to Announce Second Quarter Financial Results

Reuters
·
Jul 23

Corcept Therapeutics Schedules Second-quarter Results Conference Call

Reuters
·
Jul 23

Corcept Therapeutics (CORT) Stock Could Trade At A Discount As Its 346% Run Looms

Simply Wall St.
·
Jul 18

Corcept Therapeutics CFO Atabak Mokari Disposes of 40,000 Common Shares for $3.52 Million

Reuters
·
Jul 18

Is Corcept Therapeutics (CORT) Fully Valued On Its Russell Index Removal?

Simply Wall St.
·
Jul 10

Corcept Chief Development Officer William Guyer Disposes of USD 1.87 Million in Common Shares

Reuters
·
Jul 09

Corcept Endocrinology President Sean Maduck Sells USD 2.19 Million of Corcept Therapeutics Shares

Reuters
·
Jul 07

Does Corcept’s Exit From Russell Defensive Indexes Reframe Its Risk Profile And Investor Base (CORT)?

Simply Wall St.
·
Jul 05

Is Corcept Therapeutics (CORT) Undervalued On Its Russell Index Removal?

Simply Wall St.
·
Jul 02

Corcept Therapeutics Rocked by Major Insider Stock Sale

TIPRANKS
·
Jun 19

Corcept director David Mahoney disposes of 20,000 shares worth $1.69 million

Reuters
·
Jun 19

Corcept Therapeutics (CORT) Stock After 114% YTD Surge Is The Rally Justified

Simply Wall St.
·
Jun 18

Corcept CFO Atabak Mokari sells common shares worth $3.22 million

Reuters
·
Jun 18

Corcept Therapeutics resubmits NDA for Relacorilant in Cushing’s Syndrome

TIPRANKS
·
Jun 18

Corcept resubmits FDA NDA for relacorilant in Cushing’s syndrome, expects six-month review

Reuters
·
Jun 18

Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients With Cushing’s Syndrome

THOMSON REUTERS
·
Jun 18